Samsung Bioepis, a subsidiary of Samsung Epis Holdings, said on the 14th it has begun a phase 1 clinical trial of SBE303, an antibody-drug conjugate (ADC) investigational therapy.
According to ClinicalTrials, the U.S. National Institutes of Health (NIH) clinical trial registry, the phase 1 trial of SBE303 that began in March will enroll 149 patients with advanced solid tumors worldwide through July 2030. The trial will evaluate the safety, tolerability and efficacy of SBE303.
SBE303 is designed to target a protein called "Nectin-4," which is highly expressed in tumor cells. It is the first new drug developed by Samsung Bioepis. In Korea this year, it also received approval for a phase 1 clinical trial plan.
※ This article has been translated by AI. Share your feedback here.